Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-215

Hi,

From my reading of the results and presentation it seems to me that the research was not only to find out the efficacy of DMX200 but to confirm efficacy in as many patient group as possible.

Like many have pointed out, at first it may look as if the results were not ideal. But in hindsight I think if I had known the research design, and been more knowledgeable about kidney disease, it would be clear that this phase 2b trial was not designed to PROVE efficacy in all patients but to figure out the patient profile where efficacy occurs. It is even more obvious when considering the other research designs only targeting cases at a certain severity level whilst DXB took on board all patients. I trust that anyone with a medical background would be able to see that this is more about proving concepts and patient scoping, than about trying to show statistically significant results at all levels.

As an inexperienced investor, I trusted in DXB and am no less confident now. Definite oversell, I bought more. Clearly, this company knows what it is doing.
Look at the last capital raise. My guess is, they knew the SP was reasonable at the time.

Not understanding the DKD Phase 2b research design and purpose was the first mistake. It is no wonder that we now have people not understanding the results and selling.

Now I wish, I could have gotten my hands on the research design. And this is a learning journey for me. Please do help to point me to the right direction if you know where the research designs are kept. For future references when I invest in more biotechs.

My two cents.